Syqe Medical

About Syqe Medical

Syqe Medical, founded in 2011 by Perry Davidson, is a Tel Aviv-based pharma-tech company that has developed a metered-dose inhaler for medical cannabis. Davidson, who previously co-founded Israel's first legal medical cannabis company, Tikun Olam, established Syqe to address the critical issue of inconsistent dosing in cannabis treatments. His experience in the regulation of controlled substances and his vision to legitimize cannabis as a mainstream medical treatment have been central to the company's trajectory.

The company's core product is the SyqeAir Inhaler, a device designed to deliver precise, pharmaceutical-grade doses of cannabis vapor. This technology allows physicians to prescribe cannabis with the same level of precision as traditional medicines, ensuring patients receive a consistent and effective dose while minimizing psychoactive side effects. The inhaler uses pre-loaded cartridges containing granulated raw cannabis, which is heated and aerosolized, allowing for rapid symptom relief, often within minutes. A key feature is its ability to administer doses as small as 100 micrograms, enabling a tailored treatment approach. The device also connects wirelessly, allowing for remote monitoring and dose adjustments by clinicians.

Syqe Medical operates in the health tech and medical cannabis markets, serving patients suffering from conditions like chronic pain and PTSD. Its business model revolves around the sale of the inhaler device and the recurring revenue from its proprietary cannabis cartridges. The company has established significant partnerships, including a distribution agreement with Teva Pharmaceutical Industries in Israel. Syqe has received regulatory approval for its device in Israel and Canada, and recently gained ARTG approval in Australia. A major milestone is the pending acquisition by tobacco giant Philip Morris, which plans to invest significantly to help Syqe obtain FDA approval in the U.S. This acquisition, facilitated through Philip Morris's subsidiary Vectura, could value Syqe at up to $650 million, positioning it as a major player in the global medical cannabis industry.